$11.39
-1.30% (Daily)
Market Cap
$1.51B
Revenue
$N/A
Rank by MCap
#1027
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Vladimir Coric M.D.
Headquarters
New Haven, CT
Employees
256
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 ...
Loading chart…